RT Journal Article
SR Electronic
T1 Effects of probiotics in uncontrolled asthma
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 169
DO 10.1183/23120541.LSC-2022.169
VO 8
IS suppl 8
A1 Catherine Moermans
A1 Sophie Graff
A1 Medard Laurie
A1 Schleich Florence
A1 Virginie Paulus
A1 Françoise Guissard
A1 Monique Henket
A1 Renaud Louis
YR 2022
UL http://openres.ersjournals.com/content/8/suppl_8/169.abstract
AB Introduction: Refractory asthma still represents a certain percentage of asthmatic patients despite the use of high medication. There is a need for new therapeutics allowing a better asthma control. Probiotics are able to modulate the intestinal microbiota homeostasis as well as the immune system, to moderate inflammation and appeared to be very well tolerated and safe.Goal: The goal of this study was to assess if probiotics have a beneficial impact on refractory asthma.Methods: The randomized double blind placebo control study was performed at the CHU of Liege (Clinicaltrial.org ID: NCT03341403). Fifty-five uncontrolled asthmatics patients were included. Patients received the dietary Supplement Synbiotic “Probiotical®/Bactecal®” 3 pills a day or a placebo during 3 months. Patients were evaluated before and 1-3-6 months for the lung function, the exhaled nitric oxide value, the inflammatory blood and sputum profiles and the quality of life and asthma control assessed by questionnaires: asthma control test (ACT), asthma control questionnaire (ACQ), asthma quality of life questionnaire (AQLQ ). This study was approved by the Ethics committee of CHU Liege (2017/248) and all subjects gave written informed consent for participation.Results: The ACQ and AQLQ scores improved significantly in the probiotic group at 3 months which was not the case in the placebo group. Also, the FEV1/FVC post bronchodilation improved at 3 months compared to baseline in the probiotic group only. Finally, the IgE, fibrinogen and neutrophils blood levels decreased at 1 month after probiotics.Conclusions: Probiotics may have a valuable impact in refractory asthma. These promising results need to be validated in a larger population of asthmatic patients.FootnotesCite this article as ERJ Open Research 2022; 8: Suppl. 8, 169.This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).